Navigation Links
NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Date:5/28/2008

SOPHIA ANTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the completion of patient enrollment in the third pivotal phase 3 clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have been randomized in 120 clinical centers in North America and Europe in this study, which is the final phase 3 trial in NicOx' clinical plan for the regulatory filing of naproxcinod. The objective of this study is to assess naproxcinod's efficacy in relieving the signs and symptoms of osteoarthritis of the hip and provide additional safety data, including further information on naproxcinod's blood pressure profile in comparison to another anti-inflammatory medication. Results from this study are expected in Q4 2008 and NicOx projects the filing of a New Drug Application (NDA) in mid-2009.

NicOx is currently in the final stages of developing naproxcinod as an investigational drug for treating the signs and symptoms of osteoarthritis. Naproxcinod is the most advanced compound in a novel class of anti-inflammatory agents known as the Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs). The 303 study follows the previous two pivotal phase 3 trials. Successful results were obtained in the 301 phase 3 study, in patients with osteoarthritis of the knee (see press release of October 27, 2006). These data demonstrated superior efficacy to placebo. Data collected suggested that naproxcinod could have no detrimental effect on blood pressure, in contrast to naproxen, a widely used non-steroidal anti-inflammatory drug (NSAID). NSAIDs are known to have the tendency to elevate blood pressure to an extent that may increase the rate of serious cardiovascular adverse events, such as heart attack and stroke.

The 302 study for naproxcinod in patients with osteoarthritis of the knee (see press release of April 3, 2007) is due to report results in Q3 2008.

Maarten Beekman, Vice
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
2. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
7. NicOx Naproxcinod ABPM Data Presented at American Heart Association
8. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
9. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 Reportbuyer.com has added a new ... Lasers and Energy Devices Market Outlook to 2020, ... Brazil Aesthetic Lasers and Energy Devices Market ... GlobalData,s new report, "Brazil Aesthetic Lasers and ... market data on the Brazil Aesthetic Lasers and ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... Drug Discovery Technologies - A Global Market Overview ... The development of new drugs for treating ... in addition to consuming a lot of time. ... involves the utilizing high-throughput screening of large chemical ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Global Generic Pharmaceuticals ... The Global Generic Pharmaceuticals Industry Report ... evaluation of the Global Generic Pharmaceuticals Industry Report. ...
... Ill., Dec. 8, 2010 Life Spine announced today ... the OCTAVE Posterior Fusion System, which is intended for ... achieving fusion in conjunction with bone graft. The U.S. ... to the OCTAVE System last month. ...
Cached Medicine Technology:Reportlinker Adds Global Generic Pharmaceuticals Industry Report 2Reportlinker Adds Global Generic Pharmaceuticals Industry Report 3Reportlinker Adds Global Generic Pharmaceuticals Industry Report 4Reportlinker Adds Global Generic Pharmaceuticals Industry Report 5Reportlinker Adds Global Generic Pharmaceuticals Industry Report 6Reportlinker Adds Global Generic Pharmaceuticals Industry Report 7
(Date:9/2/2014)... Viejo, California (PRWEB) September 02, 2014 ... plugins have announced a new ProIntro Lesson from Pixel ... to create easy and fresh-looking titles,” said Christina Austin, ... professional and armature, ProIntro is a definite game changer.” ... with the ProIntro Lesson from Pixel Film Studios. ProIntro ...
(Date:9/2/2014)... 02, 2014 Aeroflow Healthcare, an industry ... Southeast, announced the opening of its new office to ... is: 310 Business Parkway, Suite D, Greer, SC 29651. ... patients with a more convenient location in the Greenville ... Healthcare and the physicians, hospitals and patients we serve, ...
(Date:9/2/2014)... September 02, 2014 NOVAtime Technology, ... solution development company, announced today that Avon Health ... has upgraded to NOVAtime 4000 Time and ... with NOVAtime’s latest smart clock, the NT7000 ... Valley of Connecticut is an award-winning nursing facility ...
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 Attorney ... as the 2015 "Lawyer of the Year" for Medical ... Lubin & Meyer PC, Boston, and has been selected for ... 2008. Only one lawyer in each practice area and designated ... based on particularly impressive voting averages received during the peer-review ...
(Date:9/2/2014)... September 02, 2014 “Harmonicas have ... a decade, primarily to help people with COPD ... are three developed systems,” says Dana Keller, PhD, ... differ, the goals are much the same – ... some type of harmonica.” , The three approaches ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3
... ... offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital voice recorder ... consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in the United States, ...
... 9 June 2009 - Researchers have been seeking ... impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) ... may contribute to the underlying neurobiology of this ... stimulate NMDA receptors administered large amounts of substances, ...
... DNA binding compound has proved surprisingly effective at binding to ... touched within two minutes. The DNA binding properties of the ... the University of Warwick by Professor Mike Hannon and Professor ... of Birmingham). However the strength of its antibiotic powers have ...
... June 9 BioMarin Pharmaceutical Inc. (Nasdaq: ... clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) ... expects to initiate the Phase 2 clinical study in ... (IRB) approval from the clinical trial sites. The ...
... Protein Widely Expressed on Tumors and Tumor Blood Vessel ... Morphotek(R), Inc., a subsidiary of Eisai Corporation of North ... (FDA) cleared its investigational new drug (IND) application to ... tumors. MORAb-004 targets endosialin, a protein expressed on cells ...
... Bruce Matter has joined healthcare IT software provider, ... growth and client satisfaction. Peminic, with offices in Princeton, ... solutions to over 400 acute care and other healthcare ... legal matters. , , Teaming with hospitals, health ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:Animal model for schizophrenia identifies a novel approach for treating cognitive impairments 2Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 2Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 3Health News:Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study 4Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Industry Recognized and Trusted Leader, Bruce Matter, Joins Healthcare IT Company, Peminic, Inc. as Company Growth in the Areas of Patient Safety, Risk Management, and Patient Satisfaction Accelerates 2
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... anti-TG test kit is a solid phase ... It is designed for the quantitative measurement ... in serum or plasma. The microplate is ... controls and patient samples are pipetted into ...
Medicine Products: